Latest long-term analysis, including more than three years of follow-up data of patients with Grade 2 IDH-mutant glioma treated with VORANIGO® (vorasidenib), will be presented in a rapid oral session on May 31 at 4:36 p.m. CDT Results show median progression-free survival among patients...
Hence then, the article about servier to present extended follow up results from the phase 3 indigo trial showing durable and sustained treatment benefits of voranigo vorasidenib at asco 2026 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Servier to Present Extended Follow-Up Results from the Phase 3 INDIGO Trial Showing Durable and Sustained Treatment Benefits of VORANIGO® (vorasidenib) at ASCO 2026 )
Also on site :
- I worked with Trump. I know why he is being so easily goaded into a forever war
- Shakira Brings Out Tyla, Ed Sheeran & Burna Boy at Her First Show Post FIFA World Cup in New York City
- ‘Critic to Israel’: Document reveals how Israel scrutinised global NGOs